Quarterly report pursuant to Section 13 or 15(d)

4. INTANGIBLE ASSETS

v3.19.1
4. INTANGIBLE ASSETS
3 Months Ended
Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
4. INTANGIBLE ASSETS

Intangible assets at March 31, 2019 and December 31, 2018 consist of the following:

    March 31, 2019   December 31, 2018
        Accumulated           Accumulated    
    Cost   Amortization   Net   Cost   Amortization   Net
Trademark and other intangible rights related to Nabi-HB   $ 4,100,046     $ 1,073,821     $ 3,026,225     $ 4,100,046     $ 927,391     $ 3,172,655  
Rights to intermediates     907,421       237,659       669,762       907,421       205,250       702,171  
Customer contract     1,076,557       979,367       97,190       1,076,557       946,971       129,586  
    $ 6,084,024     $ 2,290,847     $ 3,793,177     $ 6,084,024     $ 2,079,612     $ 4,004,412  

 

All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets for the three months ended March 31, 2019 and 2018 was $0.2 million. Estimated aggregate future aggregate amortization expense for the next five years is expected to be as follows: 

 

  Remainder of 2019     $ 633,704  
  2020       715,352  
  2021       715,352  
  2022       715,352  
  2023       715,352